{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T03:25:58Z","timestamp":1765423558119,"version":"3.28.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["HNO"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00106-024-01522-y","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T14:59:19Z","timestamp":1731077959000},"page":"876-884","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Spezielle Tumorentit\u00e4ten im Kopf-Hals-Bereich: Karzinome von Nasopharynx, Speicheldr\u00fcsen, Nasenhaupt\/-nebenh\u00f6hlen und Schilddr\u00fcse","Special entities of the head and neck region: cancers of the nasopharynx, (para)nasal cavities, salivary glands, and the thyroid gland"],"prefix":"10.1007","volume":"72","author":[{"given":"Henrike B.","family":"Zech","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian S.","family":"Betz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,8]]},"reference":[{"key":"1522_CR1","unstructured":"NCCN (2024) NCCN Leitlinien Kopf-Hals-Tumore 4.2024. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1437. Zugegriffen: 31. Juli 2024"},{"key":"1522_CR2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.oraloncology.2016.12.016","volume":"66","author":"S Alfieri","year":"2017","unstructured":"Alfieri\u00a0S, Granata\u00a0R, Bergamini\u00a0C et\u00a0al (2017) Systemic therapy in metastatic salivary gland carcinomas: A\u00a0pathology-driven paradigm? Oral Oncol 66:58\u201363","journal-title":"Oral Oncol"},{"key":"1522_CR3","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1097\/PAP.0000000000000391","volume":"30","author":"B Alzumaili","year":"2023","unstructured":"Alzumaili\u00a0B, Sadow\u00a0PM (2023) IDH2-Mutated Sinonasal Tumors: A\u00a0Review. Adv Anat Pathol 30:104\u2013111","journal-title":"Adv Anat Pathol"},{"key":"1522_CR4","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.annonc.2022.11.011","volume":"34","author":"P Bossi","year":"2023","unstructured":"Bossi\u00a0P, Chan\u00a0AT, Even\u00a0C et\u00a0al (2023) ESMO-EURACAN Clinical Practice Guideline update for nasopharyngeal carcinoma: adjuvant therapy and first-line treatment of recurrent\/metastatic disease. Ann Oncol 34:247\u2013250","journal-title":"Ann Oncol"},{"key":"1522_CR5","doi-asserted-by":"publisher","first-page":"11111","DOI":"10.1200\/JCO.2024.42.16_suppl.11111","volume":"42","author":"MS Brose","year":"2024","unstructured":"Brose\u00a0MS, Robinson\u00a0B, Wirth\u00a0LJ et\u00a0al (2024) Comparative patient-reported tolerability (PRT): A\u00a0multiplicity-controlled analysis of LIBRETTO-531, a\u00a0randomized controlled trial (RCT) in medullary thyroid cancer (MTC). JCO 42:11111\u201311111","journal-title":"JCO"},{"key":"1522_CR6","doi-asserted-by":"publisher","first-page":"6095","DOI":"10.1200\/JCO.2024.42.16_suppl.6095","volume":"42","author":"ME Cabanillas","year":"2024","unstructured":"Cabanillas\u00a0ME, Lin\u00a0JJ, Brose\u00a0MS et\u00a0al (2024) Long-term efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion thyroid carcinoma (TC). JCO 42:6095\u20136095","journal-title":"JCO"},{"key":"1522_CR7","doi-asserted-by":"publisher","first-page":"S1294","DOI":"10.1016\/j.annonc.2022.07.1725","volume":"33","author":"JC Castillon","year":"2022","unstructured":"Castillon\u00a0JC, Plana\u00a0M, Castelo\u00a0B et\u00a0al (2022) 1645O Durvalumab (D) plus tremelimumab (T) for the treatment of patients with progressive, refractory advanced thyroid carcinoma: The DUTHY (GETNE-T1812) trial. Ann Oncol 33:S1294\u2013S1295","journal-title":"Ann Oncol"},{"key":"1522_CR8","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/S0140-6736(23)00020-X","volume":"401","author":"DW Chen","year":"2023","unstructured":"Chen\u00a0DW, Lang\u00a0BHH, Mcleod\u00a0DSA et\u00a0al (2023) Thyroid cancer. Lancet 401:1531\u20131544","journal-title":"Lancet"},{"key":"1522_CR9","doi-asserted-by":"publisher","first-page":"6072","DOI":"10.1200\/JCO.2024.42.16_suppl.6072","volume":"42","author":"Q-Y Chen","year":"2024","unstructured":"Chen\u00a0Q\u2011Y, Mai\u00a0H\u2011Q, Guo\u00a0S\u2011S et\u00a0al (2024) Induction-concurrent versus concurrent-adjuvant chemoradiotherapy in patients with high-risk N2\u20133 nasopharyngeal carcinoma: An open-label, randomised, controlled, phase\u00a03\u00a0trial. JCO 42:6072\u20136072","journal-title":"JCO"},{"key":"1522_CR10","doi-asserted-by":"publisher","first-page":"e18062","DOI":"10.1200\/JCO.2024.42.16_suppl.e18062","volume":"42","author":"D Ji","year":"2024","unstructured":"Ji\u00a0D, Guo\u00a0Y, Liu\u00a0X et\u00a0al (2024) A phase\u00a0II umbrella clinical trial of advanced salivary gland cancer based on molecular typing. JCO 42:e18062\u2013e18062","journal-title":"JCO"},{"key":"1522_CR11","doi-asserted-by":"publisher","first-page":"6002","DOI":"10.1200\/JCO.2024.42.16_suppl.6002","volume":"42","author":"M Kang","year":"2024","unstructured":"Kang\u00a0M, Ma\u00a0D, Gao\u00a0J et\u00a0al (2024) Endostar combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma (LA-NPC): A\u00a0phase\u00a0III, prospective, randomised-controlled, multicenter clinical trial. JCO 42:6002\u20136002","journal-title":"JCO"},{"key":"1522_CR12","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/alr.23262","volume":"14","author":"EC Kuan","year":"2024","unstructured":"Kuan\u00a0EC, Wang\u00a0EW, Adappa\u00a0ND et\u00a0al (2024) International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors. Int Forum Allergy Rhinol 14:149\u2013608","journal-title":"Int Forum Allergy Rhinol"},{"key":"1522_CR13","doi-asserted-by":"publisher","first-page":"6084","DOI":"10.1200\/JCO.2024.42.16_suppl.6084","volume":"42","author":"SL Liu","year":"2024","unstructured":"Liu\u00a0SL, Mai\u00a0H\u2011Q, Wen\u00a0D et\u00a0al (2024) Neoadjuvant and adjuvant toripalimab for high-risk locoregionally advanced nasopharyngeal carcinoma: A\u00a0randomized, double-blind, placebo-controlled phase\u00a02\u00a0trial. JCO 42:6084\u20136084","journal-title":"JCO"},{"key":"1522_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-019-6459-6","volume":"19","author":"Y Lu","year":"2019","unstructured":"Lu\u00a0Y, Chen\u00a0D, Liang\u00a0J et\u00a0al (2019) Administration of nimotuzumab combined with cisplatin plus 5\u2011fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a\u00a0multicenter randomized controlled study. BMC Cancer 19:1\u201310","journal-title":"BMC Cancer"},{"key":"1522_CR15","doi-asserted-by":"publisher","first-page":"6000","DOI":"10.1200\/JCO.2022.40.16_suppl.6000","volume":"40","author":"J Ma","year":"2022","unstructured":"Ma\u00a0J, Tang\u00a0L\u2011L, Guo\u00a0R et\u00a0al (2022) Radiotherapy alone versus concurrent chemoradiotherapy in intermediate risk nasopharyngeal carcinoma: A\u00a0multicentre, open-label, noninferiority, randomised phase\u00a0III trial. JCO 40:6000\u20136000","journal-title":"JCO"},{"key":"1522_CR16","doi-asserted-by":"publisher","first-page":"6001","DOI":"10.1200\/JCO.2024.42.16_suppl.6001","volume":"42","author":"H-Q Mai","year":"2024","unstructured":"Mai\u00a0H\u2011Q, Liu\u00a0SL, Chen\u00a0Q\u2011Y et\u00a0al (2024) Tislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: Interim analysis of a\u00a0multicenter, randomized, placebo-controlled, double-blind, phase\u00a03\u00a0trial. JCO 42:6001\u20136001","journal-title":"JCO"},{"key":"1522_CR17","doi-asserted-by":"publisher","first-page":"11234","DOI":"10.1002\/cam4.5815","volume":"12","author":"U Nindra","year":"2023","unstructured":"Nindra\u00a0U, Hurwitz\u00a0J, Forstner\u00a0D et\u00a0al (2023) A systematic review of neoadjuvant and definitive immunotherapy in locally advanced head and neck squamous cell carcinoma. Cancer Med 12:11234\u201311247","journal-title":"Cancer Med"},{"key":"1522_CR18","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S1470-2045(23)00163-8","volume":"24","author":"C Petit","year":"2023","unstructured":"Petit\u00a0C, Lee\u00a0A, Ma\u00a0J et\u00a0al (2023) Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis. Lancet Oncol 24:611\u2013623","journal-title":"Lancet Oncol"},{"key":"1522_CR19","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00106-023-01404-9","volume":"72","author":"T Romer","year":"2024","unstructured":"Romer\u00a0T, Vokuhl\u00a0C, Staatz\u00a0G et\u00a0al (2024) Combination of nivolumab with standard induction chemotherapy in children and adults with EBV-positive nasopharyngeal carcinoma : Protocol of a\u00a0prospective multicenter phase\u00a02\u00a0trial. HNO 72:423\u2013439","journal-title":"HNO"},{"key":"1522_CR20","volume-title":"Die Rolle der Chemotherapie im Kontext der Bestrahlung beim Nasopharynxkarzinom: Update der MAC-NPC-Netzwerk-Metaanalyse","author":"A R\u00fchle","year":"2023","unstructured":"R\u00fchle\u00a0A, Nicolay\u00a0NH (2023) Die Rolle der Chemotherapie im Kontext der Bestrahlung beim Nasopharynxkarzinom: Update der MAC-NPC-Netzwerk-Metaanalyse. Springer"},{"key":"1522_CR21","doi-asserted-by":"publisher","first-page":"e18075","DOI":"10.1200\/JCO.2024.42.16_suppl.e18075","volume":"42","author":"K Sehgal","year":"2024","unstructured":"Sehgal\u00a0K, Pappa\u00a0T, Barletta\u00a0JA et\u00a0al (2024) Dual immune checkpoint inhibition with nivolumab and ipilimumab (N+I) in patients with advanced anaplastic thyroid carcinoma (ATC). JCO 42:e18075\u2013e18075","journal-title":"JCO"},{"key":"1522_CR22","doi-asserted-by":"publisher","first-page":"e18063","DOI":"10.1200\/JCO.2024.42.16_suppl.e18063","volume":"42","author":"L Shih","year":"2024","unstructured":"Shih\u00a0L, Wu\u00a0V, Ng\u00a0K et\u00a0al (2024) Long term outcomes in patients with recurrent\/metastatic (R\/M) salivary gland cancer (SGC) treated with immune checkpoint inhibitors (ICI). JCO 42:e18063\u2013e18063","journal-title":"JCO"},{"key":"1522_CR23","doi-asserted-by":"crossref","unstructured":"Steuer CE, Lubin D, Adeyelu TT et\u00a0al (2024) Genomic and immune profiling of rare non-squamous sinonasal tumors. In: American Society of Clinical Oncology, (https:\/\/meetings.asco.org\/)","DOI":"10.1200\/JCO.2024.42.16_suppl.e18008"},{"key":"1522_CR24","doi-asserted-by":"publisher","first-page":"e18008","DOI":"10.1200\/JCO.2024.42.16_suppl.e18008","volume":"42","author":"CE Steuer","year":"2024","unstructured":"Steuer\u00a0CE, Lubin\u00a0D, Adeyelu\u00a0TT et\u00a0al (2024) Genomic and immune profiling of rare non-squamous sinonasal tumors. JCO 42:e18008\u2013e18008","journal-title":"JCO"},{"key":"1522_CR25","doi-asserted-by":"publisher","first-page":"100602","DOI":"10.1016\/j.esmoop.2022.100602","volume":"7","author":"C Van Herpen","year":"2022","unstructured":"Van Herpen\u00a0C, Vander Poorten\u00a0V, Skalova\u00a0A et\u00a0al (2022) Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up. ESMO Open 7:100602","journal-title":"ESMO Open"},{"key":"1522_CR26","doi-asserted-by":"publisher","first-page":"6024","DOI":"10.1200\/JCO.2024.42.16_suppl.6024","volume":"42","author":"S Wu","year":"2024","unstructured":"Wu\u00a0S, Wang\u00a0R, Yu\u00a0Y et\u00a0al (2024) Efficacy of nimotuzumab added to concurrent chemoradiotherapy after induction chemotherapy for patients with locally advanced nasopharyngeal carcinoma. JCO 42:6024\u20136024","journal-title":"JCO"},{"key":"1522_CR27","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1200\/JCO.2024.42.16_suppl.6080","volume":"42","author":"C Xu","year":"2024","unstructured":"Xu\u00a0C, Shen\u00a0L, Yang\u00a0K\u2011Y et\u00a0al (2024) Nivolumab combined with radical chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): An investigator-initiated, open-label, multicenter, single-arm, phase\u00a0II clinical trial. JCO 42:6080\u20136080","journal-title":"JCO"},{"key":"1522_CR28","doi-asserted-by":"publisher","first-page":"TPS3183","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS3183","volume":"42","author":"E Xue","year":"2024","unstructured":"Xue\u00a0E, Bracken-Clarke\u00a0DM, Reed\u00a0M et\u00a0al (2024) Phase\u00a0II study of enasidenib in IDH2-mutated malignant sinonasal and skull base tumors. JCO 42:TPS3183\u2013TPS3183","journal-title":"JCO"},{"key":"1522_CR29","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11654-024-00560-w","volume":"19","author":"H Zech","year":"2024","unstructured":"Zech\u00a0H, Matnjani\u00a0G, Schafhausen\u00a0P et\u00a0al (2024) Nasopharynxkarzinom\u2013ein aktueller \u00dcberblick \u00fcber eine spezielle Tumorentit\u00e4t. Best Practice Onkologie 19:74\u201383","journal-title":"Best Practice Onkologie"},{"key":"1522_CR30","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s00106-022-01157-x","volume":"70","author":"HB Zech","year":"2022","unstructured":"Zech\u00a0HB, Betz\u00a0CS (2022) Spezielle Tumorentit\u00e4ten im Kopf-Hals-Bereich. HNO 70:278\u2013286","journal-title":"HNO"}],"container-title":["HNO"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00106-024-01522-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00106-024-01522-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00106-024-01522-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T17:02:35Z","timestamp":1731949355000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00106-024-01522-y"}},"subtitle":["Post ASCO 2024"],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1522"],"URL":"https:\/\/doi.org\/10.1007\/s00106-024-01522-y","relation":{},"ISSN":["0017-6192","1433-0458"],"issn-type":[{"type":"print","value":"0017-6192"},{"type":"electronic","value":"1433-0458"}],"subject":[],"published":{"date-parts":[[2024,11,8]]},"assertion":[{"value":"29 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"H.B.\u00a0Zech hat Referentenhonorare von MSD, Merck, BMS, Sanofi und Regeneron erhalten. C.S.\u00a0Betz gibt an, dass keine Interessenkonflikte vorliegen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}